EFFECT OF PROLACTIN AND BROMOCRIPTINE ON GROWTH OF TRANSPLANTED HORMONE-DEPENDENT MOUSE MAMMARY TUMOURS*

P. BRIAND, S. M. THORPE AND J. L. DAEHNFELDT
(with the technical assistance of M. Hansen, U. Haerslev and J. Krogsgaard Petersen)

From The Fibiger Laboratory†, Ndr. Frihavnsgade 70, DK-2100 Copenhagen 0, Denmark

Received 28 August 1976 Accepted 25 January 1977

Summary.—Administration of ovine prolactin alone supported growth of hormone-dependent GR mouse mammary tumours. Growth of hormone-independent tumours was not stimulated. Furthermore, administration of bromocriptine, a compound that inhibits release of prolactin from the pituitary gland, was shown to inhibit the growth of hormone-dependent tumours in animals receiving treatment with progesterone + oestrone. Administration of prolactin or bromocriptine to mice bearing tumours that grew independently of progesterone + oestrone treatment had no influence on tumour growth. We conclude that direct as well as indirect evidence has been found for the involvement of prolactin in the growth of transplanted, hormone-dependent GR mouse mammary tumours.

Clinical results have demonstrated the importance of oestrogens in the growth regulation of some breast cancers (Jensen et al., 1973). Other hormones, such as prolactin, may be involved in the growth of mammary cancer. Prolactin is already known to be essential for the growth of many rat mammary tumours (for review, see Boyns and Griffiths, 1972).

This communication demonstrates, directly and indirectly, that prolactin supports growth of transplantable GR mouse mammary tumours that grow in spayed mice treated with progesterone plus oestrone and do not grow in untreated spayed mice.

MATERIALS AND METHODS

Chemicals.—Progesterone and oestrone were generously provided by Leo Pharmaceuticals, Ballerup, Denmark. Bromocriptine (2-Br-D-ergokryptine-methanesulphonate) was donated by Sandoz, Basel, Switzerland. Ovine prolactin (20–25 iu/mg) was supplied by Ferring AB, Malmö, Sweden. The remaining chemicals were of analytical grade.

Tumour model. Mammary carcinomas were induced in spayed mice of the GRS/AFib strain according to the method of van Nie (personal communication, 1970). Ten-to-12-week-old female mice were spayed and immediately treated with progesterone plus oestrone (p + o). Progesterone pellets prepared from a paste of progesterone and olive oil were injected s.c. once a week at a dose of 5–10 mg. Oestrone was dissolved in ethanol and added to the drinking water (redistilled water) at a concentration of 0-5 µg/ml.

S.c. transplantation of induced tumours was carried out using either minced tumour tissue or tumour cells isolated enzymatically according to the method of Wiepjes and Prop (1970) modified by excluding the use of DNase. Each animal received either 100 µl of minced tumour tissue or 7–20 × 10⁶ tumour cells.

Hormone-dependent (HD) tumours were defined as tumours that grow progressively in (p + o)-treated spayed mice but not in untreated spayed mice. Hormone-independent (HI) tumours, on the other hand, grow
equally well in (p + o)-treated and untreated spayed animals.

Ovine prolactin was dissolved in 50 mM sodium bicarbonate, pH 9.85, to yield a final concentration of 0.5 mg/ml. Aliquots were stored at −20°C. 0.5 mg prolactin was injected i.p. 3 × daily at 6–10-h intervals.

Bromocriptine was dissolved in ethanol, diluted 1/10 in H₂O, and 0.2 mg in 100 μl was administered s.c. daily.

Experiments with prolactin.—Growth of both HD and HI tumours was investigated during administration of prolactin. All the HD tumours were in the first transplant generation, while the HI tumours were either in the first or in the eighth transplant generation. In each experiment, 13–24 spayed mice received transplants of the same tumour. When the transplants had formed a tumour of 0.5–1 cm³, p + o administration was discontinued in the experiments with HD tumours. Although the effects of progesterone are evident in the vaginal smear up to 4 weeks after implantation of 3 mg progesterone (Röpke, 1975), the tumours regressed to half size within 1–2 weeks. At that time the animals were divided into 3 or 4 groups of 3–6 animals and treated as follows:

Group I, p + o: 5–10 mg of progesterone (3 pellets) s.c. per week + 0.5 μg/ml of oestrone in the drinking water.

Group II, prolactin: 50 μg (100 μl) of prolactin i.p. 3 × daily at intervals of 6–10 h.

Group III, controls: 100 μl of bicarbonate buffer i.p. 3 × daily at intervals of 6–10 h.

Group IV, p + o + prolactin: p + o treatment as in Group I, and prolactin treatment as in Group II.

Tumour growth was followed by measuring the size of the tumours with a slide caliper, as described by Rockwell, Kallman and Fajardo (1972). When the largest tumour in each group reached 1–2 cm³ in size, all animals in the experiment were killed.

The experiments with HI tumours were carried out in the same way, with the modifications necessary with HI tumours. Thus, all mice received p + o treatment until the tumours had attained a volume of 0.25–0.5 cm³. At this time, mice were divided into the above treatment groups (with the omission of Group IV), and tumour size was monitored as described above.

Experiments with bromocriptine.—Six mice were spayed for each of 5 experiments with HD tumours and immediately treated in the following manner: 2 were treated with p + o as above, 2 with p + o + bromocriptine (0.2 mg s.c. per day), and 2 untreated. One week later, tumour tissue from a single, primary tumour was transplanted to each of the 6 animals. HI tumours were transplanted to 4 animals only, 2 receiving treatment with bromocriptine and 2 untreated.

The animals were observed twice weekly. When the largest tumour reached approximately 1 cm³ in size, all animals within the single experiment were killed, and the tumours were removed and weighed.

Statistics

Statistical evaluation was performed with the non-parametric Wilcoxon rank-sum test.

RESULTS

The effects of prolactin, p + o + prolactin, and p + o, on regrowth of regressing HD mammary tumours, were studied in 6 experiments. The results are shown in Fig. 1. In all 6 experiments, treatment with prolactin alone supported tumour growth for several days, whereas tumours continued to regress in all control mice injected only with buffer. In each of the experiments, the final volume of the tumours in the prolactin-treated group was significantly higher (P ≤ 0.01) than that of the tumours in the control groups. Furthermore, prolactin significantly stimulated (P ≤ 0.02) (p + o)-supported tumour growth in 1 (Experiment D) of 3 experiments. Administration of prolactin had no significant effect (P > 0.10) on the growth of HI tumours (Fig. 2).

The growth of HD tumours transplanted to spayed mice receiving bromocriptine + p + o was studied in 5 experiments. In all of these, mean tumour volume was lower in animals treated with bromocriptine + p + o than in controls treated with p + o alone (Fig. 3). This difference is statistically significant (P < 0.05) as tested by the
Wilcoxon rank-sum test based on all single observations shown in the figure. Thus the zero value in Experiment 5 is also included. No tumour takes were observed in the untreated mice. In contrast, when HI tumours were transplanted to mice receiving bromocriptine, tumour growth in treated mice did not differ from that in the untreated, control mice (Fig. 4). In Experiments 9b and 10b, bromocriptine seemed to inhibit tumour growth, but in duplicate experiments with the same tumour line, this did not appear to be the case (Experiments 9a and 10a).
DISCUSSION

The importance of prolactin in mammary tumour induction has previously been established in rats and mice by demonstrating a significantly higher tumour incidence under various conditions leading to increased serum prolactin levels (Boot, 1970; Meites, 1972), and by demonstrating a significantly lower tumour incidence during administration of bromocriptine, an inhibitor of prolactin secretion (Stähelin, Burchhardt-Vischer and Flückiger, 1972; Yanai and Nagasawa, 1972; Welsch and Gribler, 1973; Chan and Cohen, 1974).

Prolactin has also been shown to stimulate the growth of pre-existing mammary tumours in DMBA-treated rats (Pearson et al., 1969; Welsch, Clemens and Meites, 1969; Nagasawa and Yanai, 1970; Leung and Sasaki, 1975). Furthermore, when prolactin secretion is diminished in carcinogen-treated rats (by administration of bromocriptine), mammary tumour growth has been found to be inhibited (Heuson, Waelbroeck-Van Gaver and Legros 1970; Nagasawa and Meites, 1970).

In the mouse, the role of prolactin in mammary tumour growth has been less thoroughly investigated. Most mouse mammary tumours are HI (Mühlbock, 1955). However, in a few inbred strains, such as the BR strains (Foulds, 1949), the DD strain (Heston, Vlahakis and Tsubura,
heterologous mice. The prolactin might regressing as The growthrate of Yannopoulos, 1963; Chan and Cohen, 1974) prolactin might be involved in the stimulation of growth of these (p + o)-dependent GR mouse mammary tumours.

We have found that administration of prolactin alone leads to regrowth of regressing GR mouse mammary tumours. The growth rate of tumours in mice treated with prolactin was not, however, as great as that in the (p + o)-treated mice. This may have been due to use of heterologous prolactin or maintenance of suboptimal levels of prolactin throughout part of the experiment. Provided that the half-life of prolactin in mice is of the same order as that found in rats (Kwa et al., 1970), very low prolactin levels would have prevailed, in spite of the fact that a very high dose of prolactin was administered. Yet another possible explanation for the above observation would be that prolactin may require oestrogen to exert its maximal effect on tumour growth, or vice versa. However, while the effects of p + o + prolactin on tumour were additive in 1/3 experiments (Fig. 1, experiment D), a potentiation of the hormone effects was not observed.

(p + o)-dependent growth was inhibited by bromocriptine. In 4/5 experiments (bromocriptine + p + o)-treated animals showed lower values than (p + o)-treated controls, without any overlapping (see Fig. 3). In the fifth experiment one of the control mice for unknown reasons did not develop any tumour. The other one produced a tumour which weighed more than the tumours in the 2 mice which received bromocriptine.

When the results of all 5 experiments were evaluated by the Wilcoxon rank-sum test the inhibitory effect of bromocriptine was found to be statistically significant. An unspecified, toxic effect of bromocriptine on tumour growth is unlikely but cannot be excluded, since animals bearing HD tumours were treated with bromocriptine for a longer period of time than animals bearing HI tumours.

A difference in time of treatment was unavoidable, since the same amount of tumour tissue was transplanted to each mouse, and the treatment period was not extended beyond the exponential growth phase of the tumour.

In conclusion, evidence has been presented for the involvement of prolactin in the growth of transplanted, hormone-dependent GR mouse mammary tumours.

We want to thank K. Roholt, Leo Pharmaceuticals, Ballerup, Denmark, for the generous supply of oestrone and...
progesterone. We are grateful to E. Flückiger, Sandoz, Basel, Switzerland, for supplying us with bromocriptine, and to Ferring, Malmö, for providing us with ovine prolactin.

This work was supported by the Danish Cancer Society and a grant from Mrs Agathe Neye. S. M. Thorpe was supported by a scholarship from the Medical Faculty of the University of Copenhagen.

REFERENCES

Boot, L. M. (1970) Prolactin and Mammary Gland Carcinogenesis. The Problem of Human Prolactin. Int. J. Cancer, 5, 167.

Boot, L. M., Kwa, H. G. & Röpcke, G. (1973) Radioimmunoassay of Mouse Prolactin. Prolactin Levels in Isograft-bearing Orchidectomized Mice. Eur. J. Cancer, 9, 185.

Boynts, R. S. & Griffiths, K. (1972) Prolactin and Carcinogenesis. Cardif: Alpha Omega Alpha.

Briand, P. & Daehnfeldt, J. L. (1973) Enzyme Patterns of Glucose Catabolism in Hormone-dependent and-independent Mammary Tumours of GR Mice. Eur. J. Cancer, 9, 763.

Chan, P. C. & Cohen, L. A. (1974) Effects of Dietary Fat, Antiestrogen, and Antiprolactin on the Development of Mammary Tumors in Rats. J. natn. Cancer Inst., 52, 25.

Foulds, L. (1949) Mammary Tumours in Hybrid Mice: Growth and Progression of Spontaneous Tumours. Br. J. Cancer, 3, 345.

Heston, W. E., Vlahakis, G. & Tsubura, Y. (1964) Strain DD, a new High Mammary Tumor Strain, and Comparison of DD with Strain C3H. J. natn. Cancer Inst., 32, 237.

Heuson, J. C., Waelbroeck-Van Gaver, C. & Legros, N. (1970) Growth Inhibition of Rat Mammary Carcinoma and Endocrine Changes Produced by 2-Br-α-Ergocryptine, a Suppressor of Lesions and Nidations. Eur. J. Cancer, 6, 355.

Jensen, E. V., Block, G. E., Smith, S. & Desombre, E. R. (1973) Hormonal Dependency of Breast Cancer. Recent Results Cancer Res., 42, 55. Ed. M. L. Griem, E. W. Jensen, S. E. Ullmann & R. W. Wisler. Berlin: Springer-Verlag.

Kim, U., Purth, J. & Yannopoulos, K. (1963) Observatons on Hormonal Control of Mammary Cancer. I. Estrogen and Mammatropes. J. natn. Cancer Inst., 31, 233.

Kwa, H. G., Feltkamp, C. A., Van der Gunten, A. A. & Verhoffstad, F. (1970) The Rate of Elimination of Prolactin as a Determinant Factor for Plasma Levels Assayed in Rat. J. Endocr., 48, 299.

Lee, A. E. (1970) Mammary Tumor Development in BR6 Mice: Ovarian Influences and 5-Hydroxytryptamine. Br. J. Cancer, 24, 581.

Leung, B. S. & Sasaki, G. H. (1975) On the Mechanism of Prolactin and Estrogen Action in 7,12-Dimethylbenz(a)anthracene-induced Mammary Carcinoma in the Rat. II. In vivo Tumor Response and Estrogen Receptor. Endocrinology, 97, 564.

Meites, J. (1972) Relation of Prolactin to Mammary Tumourigenesis and Growth in Rats. In Prolactin and Carcinogenesis. Ed. A. R. Boyes & K. Griffiths. Cardif: Alpha Omega Alpha.

Muir, S. M., Bradford, G. E. & Geschwind, L. I. (1974) Plasma Luteinizing Hormone, Follicle-stimulating Hormone and Prolactin during Pregnancy in the Mouse. Endocrinology, 94, 112.

Mühle, O. (1955) The Influence of Hormones on Spontaneous Experimental Tumours. In Simposio sugli antiomicotici (San Remo), p. 41.

Nagawa, M. & Meites, J. (1970) Suppression by Ergocornine and Iproniazid of Carcinogen-induced Mammary Tumors in Rats: Effects on Serum and Pituitary Prolactin Levels. Proc. Soc. exp. Biol. Med., 135, 469.

Nagawa, H. & Yanai, R. (1970) Effects of Prolactin or Growth Hormone on Growth of Carcino-ogen-induced Mammary Tumors of Adreno-ovariectomized Rats. Int. J. Cancer, 6, 488.

Pearson, O. H., Llerena, O., Llerena, L., Molina, A. & Butler, T. (1969) Prolactin-dependent Rat Mammary Cancer: A Model for Man? Trans. Assoc. Am. Physicians, 52, 225.

Rockwell, S. C., Kallman, R. F. & Fajardo, L. F. (1972) Characteristics of a Serially Transplanted Mouse Mammary Tumor and Its Tissue-culture-adapted Derivative. J. natn. Cancer Inst., 49, 735.

Röpcke, G. (1975) Interaction of Hypophyseal Isografts and Ovarian Hormones in Mammary Tumour Development in Mice. Thesis. p. 57. Amsterdam: Mondeel.

Sluyser, M. & Van Nie, R. (1974) Estrogen Receptor Content and Hormone-responsive growth of Mouse Mammary Tumors. Cancer Res., 34, 3253.

Squarzini, F. (1962) Responsiveness and Progression of Mammary Tumors in High-cancer-strain Mice. J. natn. Cancer Inst., 28, 911.

Stähelin, H., Burkhardt-Vischew, B. & Flückiger, E. (1969) Rat Mammary Cancer Inhibition by a Prolactin Suppressor, 2-Bromo-α-ergokryptine (CB154). Experien. 27, 915.

Van Nie, R. & Dux, A. (1971) Biological and Morphological Characteristics of Mammary Tumors in GR Mice. J. natn. Cancer Inst., 46, 885.

Van Nie, R. & Thung, P. J. (1965) Responsiveness of Mouse Mammary Tumours to Pregnancy. Eur. J. Cancer, 1, 41.

Welsch, C. W., Clemens, J. A. & Meites, J. (1969) Effects of Hypothalamic and Amygdaloid Lesions on Development and Growth of Carcinogen-induced Mammary Tumors in the Female Rat. Cancer Res., 29, 1541.

Welsch, C. W. & Grilker, C. (1973) Prophylaxis of Spontaneously Developing Mammary Carcinoma in C3H/HeJ Female Mice by Suppression of Prolactin. Cancer Res., 33, 2939.

Wiepjes, G. J. & Prop, F. J. A. (1970) Improved Method for Preparation of Single-cell Suspensions from Mammary glands of Adult Virgin Mouse. Exp Cell Res., 61, 431.

Yanai, R. & Nagawa, H. (1972) Inhibition of Mammary Tumorigenesis by Ergot Alkaloids and Promotion of Mammary Tumorigenesis by Pituitary Isografts in Adreno-ovariectomized Mice. J. natn. Cancer Inst., 48, 715.